2015 – 2016
October 9, 2023Eversense CGM System®
October 15, 2023HUMA
Huma securely allows remote collection of patient-generated data & the creation of companion items to be transfer directly to physicians.
Overview
Huma is a healthcare technology firm headquartered in London, United Kingdom. The company develops apps that securely transfer health-related information from current institutional databases, patient wearables, and other mobile devices to physicians. Huma’s immersive technology allows the remote collection of patient-generated data through therapeutic advancement, post-approval testing, real-world tracking, and the creation of digital biomarkers and companion items. Their app allows for remote patient data processing, such as e-consent, ePRO collection, biometric capturing, data consumption from wearables, cellular endpoints, and telemedicine visits.
HUMANA AI Aspect
Clinical experiments that are conducted online
The simulated clinical trial approach from Huma combines trial patients, investigators, and testing teams to speed up recruiting, increase participation, and ensure procedure adherence. Huma’s clinical trial technology lowers participant pressure and raises awareness of patient-generated data captured in the field.
Proof of the real world
Through processing and studying real-world evidence, Huma allows biopharmaceutical and medical device industries to better understand how therapies are used and performed in real-world environments.
Biomarkers of the digital age
In both health and illness, Huma’s automated phenotyping capabilities and digital biomarkers will offer more detailed, objective, and continuous pictures of human activity and work. This information is advancing predictive and personalized medicine, clinical trial accuracy, and time.
Companion digital goods
Huma’s wireless companion products enhance current therapies by making medical data collection easier. They can increase the quality of care by empowering and connecting patients, doctors, and healthcare systemsText Editor Continued. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.Lorem ipsum dolor sit amet, consectetur adipiscing elit.(1)
Huma IT and Platform
Huma’s virtual arrangements support the far-off assortment of patient-created information through periods of clinical turn of events, post-endorsement research, genuine observing, and improvement of computerized biomarkers and partner items. Their platform gives distant patient information catch, including e-assent, ePRO assortment, biometric catch, information ingestion from wearables, utilization of computerized endpoints, and telemedicine visits.
Virtual clinical trials
Huma’s virtual clinical trial arrangement interfaces preliminary members, agents, and exploration groups to speed up enrollment, drive member commitment, and convention adherence. Huma’s innovation for clinical preliminaries diminishes member troubles and improves the perceivability of patient-created information gathered in the genuine setting.
A chance to have a direct relationship with the patient
The platform allows life science organizations to fabricate a longitudinal relationship with a patient populace.
From conveying updates to members engaged with contemplates (for example, distributed outcomes and administrative endorsements) to keeping in touch with members for follow-up examinations (for example, statistical surveying and RWE), Huma’s deterrent well-being and advanced arrangements make research more human-driven.
Improving showcased treadments
Huma’s advanced partner items supplement existing medicines and care pathways by engaging patients to comprehend better and deal with their well-being. Partner items empower direct correspondence and information sharing among all life sciences partners, which changes care and improves adherence and clinical dynamics.
Their answer
Huma’s advanced items increase patient adherence through drug updates, perceivability of medicine adherence to mind groups, and engagement of patients to assume responsibility for their well-being.(2)
Huma’s Financial Aspects
Huma Therapeutics Limited today declares the fruition of its most recent subsidizing round with roughly $130 million in financing. The venture will scale Huma’s particular stage, which can control computerized ‘medical clinics at home’ broadly and support the drug and exploration enterprises to run the biggest at any point decentralized clinical preliminaries. Huma’s foundation consolidates prescient calculations, computerized biomarkers, and true information to progress proactive consideration and examination.
The new investment will be utilized to extend Huma’s advanced stage in the US, Asia, and the Middle East, with Huma being named Europe’s quickest-developing medical services organization by the Financial Times(1). Huma has established a standing as a committed to well-being innovation and advancement accomplice to four public governments (England’s NHS, Wales, Germany, and UAE).(3)
BioBase App Used for Minimizing Depressive Symptoms and Reducing Anxiety
A study evaluated the BioBase app in reducing anxiety and increasing stress management in university students by providing cognitive behavioral therapy, mindfulness, and biofeedback interventions. The app tool supplies mood assessment and reduces stress by offering diaphragmatic breathing exercises and relaxation techniques. Furthermore, BioBeam is a bracelet device that gives insight into sleep quality, heart rate, and physical activity. Universities could greatly benefit from this easily accessible app by assisting their students with its tools to reduce their anxiety and minimize depressive symptoms.(4)
Breathing Techniques for Stress Management Provided by BioBase app
Mobile apps have been used to decrease workplace stress by altering the stress response. Negative emotions could lead to negative thoughts that can increase cardiovascular disease risk in the long term. The app can provide the Papworth-Benson breathing method by recording the heart rate, which centers on diaphragmatic breathing, reducing the ventilation, which stimulates the vagus nerve when relaxation occurs.
A study that compared the effects of breathing exercises guided by the BioBase app found that heart rate variability was higher at recovery for participants who performed BioBase breathing after stress induction. Simple and highly accessible, this app is a potential solution for successful stress-management interventions by providing breathing relaxation techniques.(5)
Population Risk Factors for Severe Disease and Mortality in COVID-19: A Global Systemic Review and Meta-Analysis
COVID-19 is an infection with a wide clinical presentation, from asymptomatic to severe. Early studies identified risk factors for COVID-19, but the differences in study designs make difficult the consolidation of these findings. In this study, researchers mapped all the available evidence from two databases (PubMed and SCOPUS), trying to associate clinical, demographic, and lifestyle variables with the risk of established outcomes for individuals with COVID-19. A total of seventy-six studies were used, including almost 18 million patients. The most common variables associated with adverse outcomes included age >75, male sex, severe obesity, and active cancer.(6)
A Mobile Application for Telemonitoring of Patients with Heart Failure
Heart failure (HF) represents a big healthcare problem with significant morbidity and mortality. Around 40% of patients with HF experience death or readmission within six months after hospital discharge. This study aimed to evaluate the practicality of a telemonitoring system for patients after an HF hospitalization.
Researchers developed a cardio patient monitoring platform (CPMP) for patients’ smartphones or smartwatches and a similar application for physicians. The system allows the transmission of physiological parameters, symptoms, and activity data. The information was collected from 10 patients hospitalized for newly diagnosed HF. The CPMP was examined during the first two months after discharge. The system allowed continuous monitoring of real-life activity and correlated with traditional cardiac performance parameters like LVEF, 6-minute walk test, and quality of life questionnaires.(7)